Top

Published in:

Open Access 01-07-2019 | Myocardial Infarction

The relevance of microRNA in post-infarction left ventricular remodelling and heart failure

Authors: Mieczysław Dutka, Rafał Bobiński, Jan Korbecki

Published in: Heart Failure Reviews | Issue 4/2019

Abstract

Myocardial infarction and post-infarction left ventricular remodelling involve a high risk of morbidity and mortality. For this reason, ongoing research is being conducted in order to learn the mechanisms of unfavourable left ventricular remodelling following a myocardial infarction. New biomarkers are also being sought that would allow for early identification of patients with a high risk of post-infarction remodelling and dysfunction of the left ventricle. In recent years, there has been ever more experimental data that confirms the significance of microRNA in cardiovascular diseases. It has been confirmed that microRNAs are stable in systemic circulation, and can be directly measured in patients’ blood. It has been found that significant changes occur in the concentrations of various types of microRNA in myocardial infarction and heart failure patients. Various types of microRNA are also currently being intensively researched in terms of their usefulness as markers of cardiomyocyte necrosis, and predictors of the post-infarction heart failure development. This paper is a summary of the current knowledge on the significance of microRNA in post-infarction left ventricular remodelling and heart failure.

Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P (2012) TNF revisited: osteoprotegerin and TNF – related molecules in heart failure. Curr Heart Fail Rep 9:92–100CrossRefPubMed

Secchiero P, Corallini F, Beltrami A, Ceconi C, Bonasia V et al (2010) An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:274–277CrossRefPubMed

Bjerre M, Munk K, Sloth AD, Nielsen ST, Flyvbjerg A et al (2014) High osteoprotegerin levels predict MACCE in STEMI patients, but are not assotiated with myocardial salvage. Scand Cardiovasc J Vol 48:209–215CrossRef

Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Sørensen TB, Iversen A, Hvelplund A, Jensen JS (2012) Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 123:31–38CrossRefPubMed

Corallini F, Secchiero P, Beltrami AP, CesselliD PE et al (2012) TNF –alfa modulates the migratory response of mesenchymal stem cells to TRAIL. Cell Mol Life Sci 67:1307–1314CrossRef

Roysland R, Bonaca M, Omland T, Sabatine M, Murphy S et al (2012) Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart 98:786–791CrossRefPubMedPubMedCentral

Wojakowski W, Tendera M, Zebzda A, Michalowska A, Majka M et al (2006) Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J 27(3):283–289CrossRefPubMed

Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M et al (2004) Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110(20):3213–3220CrossRefPubMed

Kumar Singh N (2017) microRNAs databases: developmental methodologies, structural and functional annotations. Interdiscip Sci Comput Life Sci 9:357–377CrossRef

10.

Desvignes T, Batzel P, Berezikov E, Eilbeck K, Eppig JT, McAndrews MS, Singer A, Postlethwait JH (2015) microRNA nomenclature: a view incorporating genetic origins, biosynthetic pathways, and sequence variants. Trends Genet 31(11):613–626CrossRefPubMedPubMedCentral

11.

Hukowska-Szematowicz B, Deptuła W (2010) Biological role of microRNA (miRNA) – new data. Post Biol Komorki 37(3):585–597

12.

Gidlof O, Andersson P, Van Der Pals J, Gotberg M (2011) Cardiospecyfic microRNA plasma levels correlate with troponin and cardiac function in patient with ST elevation myocardial infarction, are selectively detected in urine samples. Cardiology 118:217–226CrossRefPubMed

13.

Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ (2015) MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart 101:921–928CrossRefPubMedPubMedCentral

14.

Hammond SM (2015) An overview of microRNAs. Adv Drug Deliv Rev 87:3–14CrossRefPubMedPubMedCentral

15.

Kim Y-K, Kim B, Kim VN (2016) Re-evaluation of the roles of DROSHA, Exportin 5, and DICER in microRNA biogenesis. Proc Natl Acad Sci U S A 113(13):E1881–E1889CrossRefPubMedPubMedCentral

16.

Svobodova E, Kubikova J, Svoboda P (2016) Production of small RNAs by mammalian Dicer. Eur J Phys 468:1089–1102CrossRef

17.

Johanson TM, Lew AM, Chong MMW (2013) MicroRNA-independent roles of the RNase III enzymes Drosha and Dicer. Open Biol 3:130144 https://doi.org/10.1098/rsob.130144 CrossRefPubMedPubMedCentral

18.

Kwon SC, Nguyen TA, Choi Y-G, Jo MH, Hohng S, Kim VN, Woo JS (2016) Structure of human DROSHA. Cell 164:81–90CrossRefPubMed

19.

Sperber H, Beem A, Shannon S, Jones R, Banik P, Chen Y, Ku S, Varani G, Yao S, Ruohola-Baker H (2014) miRNA sensitivity to Drosha levels correlates with pre-miRNA secondary structure. RNA 20:621–631CrossRefPubMedPubMedCentral

20.

Liu YP, Karg M, Harwig A, Herrera-Carrillo E, Jongejan A, van Kampen A, Berkhout B (2015) Mechanistic insights on the Dicer-independent AGO2-mediated processing of AgoshRNAs. RNA Biol 12(1):92–100CrossRefPubMedPubMedCentral

21.

Nguyen TA, Jo MH, Kim VN, Woo J-S et al (2015) Functional anatomy of the human Microprocessor. Cell 161:1374–1387CrossRefPubMed

22.

Wilson RC, Tambe A, Kidwell MA, Noland CL, Schneider CP, Doudna JA (2015) Dicer–TRBP complex formation ensures accurate mammalian microRNA biogenesis. Mol Cell 57(3):397–407CrossRefPubMed

23.

Guo D, Barry L, Lin SSH, Huang V, Li L-C (2014) RNAa in action: from the exception to the norm. RNA Biol 11(10):1221–1225CrossRefPubMed

24.

Gurtan AM, Sharp PA (2013) The role of miRNAs in regulating gene expression networks. J Mol Biol 425(19):3582–3600CrossRefPubMedPubMedCentral

25.

Koscianska E, Starega-Roslan J, Krzyzosiak WJ (2011) The role of Dicer protein partners in the processing of microRNA recursors. PLoS One 6(12). https://doi.org/10.1371/journal.pone.0028548

26.

H-o I, Tomari Y (2015) The functions of MicroRNAs: mRNA decay and translational repression. Trends Cell Biol 25(11):651–665CrossRef

27.

Ban YH, Oh S-C, Seo S-H, Kim S-M, Choi I-P (2017) miR - 150-mediated Foxo1 regulation programs CD8+ T cell differentiation. Cell Rep 20:2598–2611CrossRefPubMed

28.

Chen Z, Stelekati E, Kurachi M, Yu S, Cai Z, Manne S, Khan O, Yang X, Wherry EJ (2017) MiR - 150 regulates memory CD8 T cell differentiation via c-Myb. Cell Rep 20(11):2584–2597CrossRefPubMedPubMedCentral

29.

Sang W, Sun C, Zhang C, Zhang D, Wang Y et al (2016) MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway. Cell Immunol 306:35–40CrossRefPubMed

30.

King BC, Esguerra JLS, Golec E, Eliasson L, Kemper C (2016) CD46 activation regulates miR - 150 - mediated control of GLUT1 expression and cytokine secretion in human CD4+ T cells. Immunology 196(4):1636–1645CrossRef

31.

Desjarlais M, Dussault S, Dhahri W, Mathieu R, Rivard A (2017) MicroRNA-150 modulates ischemia-induced neovascularization in atherosclerotic conditions. Arterioscler Thromb Vasc Biol 37:900–908CrossRefPubMed

32.

Rajput C, Tauseef M, Farazuddin M, Yazbeck P, Amin M-R, Avin BR V, Sharma T, Mehta D (2016) MicroRNA-150 suppression of angiopoetin-2 generation and signaling is crucial for resolving vascular injury. Arterioscler Thromb Vasc Biol 36(2):380–388CrossRefPubMedPubMedCentral

33.

Wang X, Song C, Zhou X, Han X, Li J, Wang Z, Shang H, Liu Y, Cao H (2017) Mitochondria associated MicroRNA expression profiling of heart failure. Biomed Res Int 2017:1–10. https://doi.org/10.1155/2017/4042509 CrossRef

34.

Zhu X-H, Yuan Y-X, Rao S-L, Wang P (2016) LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR - 150. Eur Rev Med Pharmacol Sci 20:3653–3660PubMed

35.

Widlansky ME, Jensen DM, Wang J, Liu Y, Geurts AM et al (2018) miR - 29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol Med. https://doi.org/10.15252/emmm.201708046

36.

Lu Z, Wang F, Yu P, Wang X, Wang Y, Tang ST, Zhu HQ (2018) Inhibition of miR - 29b suppresses MAPK signaling pathway through targeting SPRY1 in atherosclerosis. Vasc Pharmacol 102:29–36. https://doi.org/10.1016/j.vph.2018.01.006 CrossRef

37.

Huang Y-G, Li J, Chen J-Y, Zhou Y-L, Cai A-P et al (2017) The Association of Circulating MiR - 29b and Interleukin-6 with subclinical atherosclerosis. Cell Physiol Biochem 44:1537–1544CrossRefPubMed

38.

Zhang H, Chen J, Shen Z, Gu J, Xu L et al (2018) Indoxyl sulfate accelerates vascular smooth muscle cell calcification via microRNA-29b dependent regulation of Wnt/β-catenin signaling. Toxicol Lett 284:29–36CrossRef

39.

Wu L, Wang Q, Guo F, Ma X, Ji H et al (2016) MicroRNA-27a induces mesangial cell injury by targeting of PPARγ, and its in vivo knockdown prevents progression of diabetic nephropathy. Sci Rep 6. https://doi.org/10.1038/srep26072

40.

Shi D-L, Shi G-R, Xie J, Du X-Z, Yang H (2016) MicroRNA-27a inhibits cell migration and invasion of fibroblast-like synoviocytes by targeting follistatin-like protein 1 in rheumatoid arthritis. Mol Cells 39(8):611–618CrossRefPubMedPubMedCentral

41.

Yao F, Yu Y, Feng L, Li J, Zhang M, Lan X, Yan X, Liu Y, Guan F, Zhang M, Chen L (2017) Adipogenic miR - 27a in adipose tissue upregulates macrophage activation via inhibiting PPARγ of insulin resistance induced by high-fat dietassociated obesity. Exp Cell Res 355:105–112CrossRefPubMed

42.

Xie X, Li S, Zhu Y, Liu L, Pan Y, Wang J, Shi W, Song Y, Yang L, Gao L, Zang W, Li M (2017) MicroRNA-27a/b mediates endothelin-1-induced PPARγ reduction and proliferation of pulmonary artery smooth muscle cells. Cell Tissue Res 369:527–539CrossRefPubMed

43.

Garikipati VNS, Krishnamurthy P, Verma SK, Khan M, Abramova T, Mackie AR, Qin G, Benedict C, Nickoloff E, Johnson J, Gao E, Losordo DW, Houser SR, Koch WJ, Kishore R (2015) Negative regulation of miR - 375 by Interleukin-10 enhances bone marrow derived progenitor cell- mediated myocardial repair and function after myocardial infarction. Stem Cells 33(12):3519–3529CrossRefPubMedPubMedCentral

44.

Boštjančiča E, Brandner T, Zidar N, Glavač D, Štajer D (2018) Down-regulation of miR - 133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation. Biomed Pharmacother 99:65–71CrossRef

45.

Bayoumi AS, Teoh JP, Aonuma T, Yuan Z, Ruan X, Tang Y, Su H, Weintraub NL, Kim IM (2017) MicroRNA-532 protects the heart in acute myocardial infarction, and represses prss23, a positive regulator of endothelial-to-mesenchymal transition. Cardiovasc Res 113:1603–1614. https://doi.org/10.1093/cvr/cvx132 CrossRefPubMedPubMedCentral

46.

Zhang M, Cheng Y-J, Sara J, Liu L-J, Liu L-P et al (2017) Circulating MicroRNA-145 is associated with acute myocardial infarction and heart failure. Chin Med J 130:51–56CrossRefPubMedPubMedCentral

47.

Latet SC, Van Herck PL, Claeys MJ, Van Craenenbroeck AH, Heine SE et al (2017) Failed downregulation of circulating microRNA-155 in the early phase after ST elevation myocardial infarction I associated with adverse left ventricular remodelling. Cardiology 138(2):91–96CrossRefPubMed

48.

Guo ML, Guo LL, Weng YQ (2017) Implication of peripheral blood miRNA - 124 in predicting acute myocardial infarction. Eur Rev Med Pharmacol Sci 21:1054–1059PubMed

49.

Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O et al (2013) A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One 8(8). https://doi.org/10.1371/journal.pone.0070644

50.

Wang YL, Gong WG, Yuan QL (2016) Effects of miR - 27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis. Genet Mol Res 2016(4):15. https://doi.org/10.4238/gmr15049070 CrossRef

51.

Li Y, Li J, Sun X, Chen J, Sun X et al (2016) MicroRNA27a functions as a tumor suppressor renal cell carcinoma by targeting epidermal growth factor receptor. Oncol Lett 11:4217–4223CrossRefPubMedPubMedCentral

52.

Kong L-Y, Xue M, Zhang Q-C, Su C-F (2017) In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway. Oncotarget 8(9):15507–15519PubMedPubMedCentral

53.

Zhang R, Xu J, Zhao J, Bai J (2017) Knockdown of miR - 27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex. Oncotarget 8(28):45213–45223PubMedPubMedCentral

54.

Ba S, Xuan Y, Long Z-W, Chen H-Y, Zheng S-S (2017) MicroRNA-27a promotes the proliferation and invasiveness of colon cancer cells by targeting SFRP1 through the Wnt/β- catenin signaling pathway. Cell Physiol Biochem 42:1920–1933CrossRefPubMed

55.

Chae D-K, Ban E, Yoo YS, Kim EE, Baik J-H et al (2017) MIR - 27a regulates the TGF-β signaling pathway by targeting SMAD2 and SMAD4 in lung cancer. Mol Carcinog 56:1992–1998CrossRefPubMed

56.

Wu F, Li J, Guo N, Wang X-H, Liao Y-Q (2017) MiRNA - 27a promotes the proliferation and invasion of human gastric cancer MGC803 cells by targeting SFRP1 via Wnt/β-catenin signaling pathway. Am J Cancer Res 7(3):405–416PubMedPubMedCentral

57.

Chen S, Sun Y-Y, Zhang Z-X, Li Y-H, Xu Z-M et al (2017) Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β- catenin pathway. Oncotarget 8(9):14708–14718PubMedPubMedCentral

58.

Quan J, Liu S, Dai K, Jin L, He T et al (2018) MicroRNA23a/242/27a as a potential diagnostic biomarker for cancer: a systematic review and metaanalysis. Mol Clin Oncol 8:159–169PubMed

59.

Lin T, Ma Q, Zhang Y, Zhang H, Yan J et al (2018) MicroRNA-27a functions as an oncogene in human osteosarcoma by targeting CCNG1. Oncol Lett 15:1067–1071PubMed

60.

Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D et al (2013) MicroRNA-150 a novel marker of left ventricular remodelling after acute myocardial infarction. Circ Cardiovasc Genet 6:290–298CrossRefPubMed

61.

Ma J-L, Guo W-L, Chen X-M (2018) Overexpressing microRNA-150 attenuates hypoxia-induced human cardiomyocyte cell apoptosis by targeting glucose-regulated protein94. Mol Med Rep 17:4181–4186PubMedPubMedCentral

62.

Li J, Zhang S (2016) microRNA-150 inhibits the formation of macrophage foam cells through targeting adiponectin receptor 2. Biochem Biophys Res Commun 476:218–224CrossRefPubMed

63.

Condorelli G, Latronico MV, Dorn GW (2010) MicroRNAs in heart disease: putative novel terapeuthic targets? Eur Heart J 31:649–658CrossRefPubMedPubMedCentral

64.

Zhu H, Fan G-C (2012) Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res 94:284–292CrossRefPubMed

65.

Zile MR, Mehurg SM, Arroyo JE, Stroud RE, DeSantis SM et al (2011) Relationship between the temporal profile of plasma microRNA and left ventricular remodelling in patients following myocardial infarction. Circ Cardiovasc Genet 4(6):614–619CrossRefPubMedPubMedCentral

66.

Zhang W-Q, Xie B-Q (2017) A meta-analysis of the relations between blood microRNA-208b detection and acute myocardial infarction. Zhang W-Q, Xie B-Q. Eur Rev Med Pharmacol Sci 21:848–854PubMed

67.

Lv P, Zhou M, He J, Meng W, Ma X, Dong S, Meng X, Zhao X, Wang X, He F (2014) Circulating miR - 208b and miR -34a are associated with left ventricular remodelling after acute myocardial infarction. Int J Mol Sci 15:5774–5788CrossRefPubMedPubMedCentral

68.

Grabmaier U, Clauss S, Gross L, Klier I, Franz WM, Steinbeck G, Wakili R, Theiss HD, Brenner C (2017) Diagnostic and prognostic value of miR - 1 and miR - 29b on adverse ventricular remodelling after acute myocardial infarction – the SITAGRAMI-miR analysis. Int J Cardiol 244:30–36CrossRefPubMed

69.

Shyu K-G, Wang B-W, Cheng W-P, Lo H-M (2015) MicroRNA-208a increases myocardial Endoglin expression and myocardial fibrosis in acute myocardial infarction. Can J Cardiol 31:679–690CrossRefPubMed

70.

Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, Dorn GW II (2010) MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106:166–175CrossRefPubMed

71.

Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE (2009) miR - 133 and miR - 30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodelling. Circ Res 104:170–178CrossRefPubMed

72.

Liu Z-H, Sun X-P, Zhou S-L, Wang H-X (2017) Research on the relations between the variation of miRNA - 184 before and after treatment of acute myocardial and prognosis. Eur Rev Pharmacol Sci 21:843–847

73.

Song Y-S, Joo HW, Park IH, Shen GY, Lee Y et al (2017) Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac miRNA - 23a and miRNA - 92 in a rat model of myocardial infarction. PLoS One 12(6). https://doi.org/10.1371/journal.pone.0179972

74.

Wang J, Huang W, Xu R, NieY CX et al (2012) MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 16(9):2150–2160CrossRefPubMedPubMedCentral

75.

Bie Z-D, Sun L-Y, Geng C-L, Meng Q-G, Lin X-J, Wang YF, Wang XB, Yang J (2016) MiR - 125b regulates SFRP5 expression to promote growth and activation of cardiac fibroblasts. Cell Biol Int 40:1224–1234CrossRefPubMed

76.

Li S-H, Guo J, Wu J, Sun Z, Han M et al (2016) miR - 17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodelling. FASEB J 27(10):4254–4265CrossRef

Title: The relevance of microRNA in post-infarction left ventricular remodelling and heart failure
Authors: Mieczysław Dutka
Rafał Bobiński
Jan Korbecki
Publication date: 01-07-2019
Publisher: Springer US
Keywords: Myocardial Infarction
Heart Failure
Published in: Heart Failure Reviews / Issue 4/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-019-09770-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The relevance of microRNA in post-infarction left ventricular remodelling and heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials

Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement

Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases

Cardiorenal syndrome in heart failure with preserved ejection fraction—an under-recognized clinical entity

Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy

Personalized physiology-guided resuscitation in highly monitored patients with cardiac arrest—the PERSEUS resuscitation protocol

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page